RxDoctor Payments Data

Saw Oo, MD

Family Medicine · Bourbonnais, ILNPI 1093813156

Payments from drug & device makers

$10,963in general payments, 2019–2025

Across 635 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$836
  • Lilly USA, LLC$752
  • Amgen$739
  • GSK$715
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$10,85299%
  • Education$1111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,963 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$105,311
Medicare patients
301
Services billed
1,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide53$71,890
TrulicityDulaglutide52$67,906
JardianceEmpagliflozin71$66,055
EliquisApixaban36$44,590
OzempicSemaglutide40$43,353
JanuviaSitagliptin Phosphate19$22,707
TradjentaLinagliptin15$20,430
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$18,211
Soliqua 100-33Insulin Glargine/Lixisenatide17$17,929
MyrbetriqMirabegron28$15,590
FarxigaDapagliflozin Propanediol14$14,492
XareltoRivaroxaban18$13,592
VascepaIcosapent Ethyl12$6,180
Icosapent Ethyl15$4,814
Fenofibrate71$3,434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,549$115,24293 claims
Boehringer IngelheimJardiance, Tradjenta$490$86,48586 claims
Lilly USA, LLCTrulicity$752$67,90652 claims
PfizerEliquis$682$44,59036 claims
MerckJanuvia$159$22,70719 claims
GSKTrelegy Ellipta$715$18,21121 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$211$17,92917 claims
Astellas Pharma US IncMyrbetriq$46$15,59028 claims
AstraZenecaFarxiga$836$14,49214 claims
Johnson & JohnsonXarelto$302$13,59218 claims
AbbVieSynthroid, Armour Thyroid$1,839$3,42454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Bourbonnais

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →